|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||103.98 - 107.35|
|52 Week Range||91.04 - 117.98|
|Beta (5Y Monthly)||0.12|
|PE Ratio (TTM)||35.82|
|Forward Dividend & Yield||1.04 (0.99%)|
|Ex-Dividend Date||Mar 03, 2021|
|1y Target Est||N/A|
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's cell-based quadrivalent seasonal influenza vaccine (QIVc) in peer-reviewed medical journal Vaccines.1 This retrospective cohort analysis indicated QIVc was more effective in reducing hospitalizations/emergency room (ER) visits caused by influenza, respiratory related hospitalizations/ER visits and all-cause hospitalizations compared with an egg-based quadrivalent influenza vaccine (QIVe) among individuals 4–64 years of age during the 2018/19 U.S. influenza season.1
Health Canada's Approval of FOCLIVIA® (An Adjuvanted, Egg-Based A Strain H5N1 Pandemic Influenza Vaccine) Meets Key Requirement as Pandemic PartnerMONTREAL, March 23, 2021 /CNW/ -- Seqirus, a world leader in influenza vaccines and pandemic response, announced today that following Health Canada's approval of FOCLIVIA® (adjuvanted, egg-based A strain H5N1 pandemic influenza vaccine), the Company is ready to fulfil its role in Canada's influenza pandemic preparedness plans.Seqirus Canada is an influenza pandemic vaccine partner to the Canadian Government through the Public Health Agency of Canada (PHAC).